Progress in breast cancer research

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2715-2717

  Polyak, Kornelia ^a,b   Vogt, Peter K ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; XL 147;

BREAST CANCER; CANCER CLASSIFICATION; CANCER RESEARCH; CELL DIVISION; EDITORIAL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR THERAPY; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA DAMAGE; FEMALE; GENETIC TESTING; GENOME, HUMAN; GENOMICS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84857410936     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201091109     Document Type: Editorial

References (31)

1. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121:3786-3788.
2. Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. (Pubitemid 32878711)
3. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-247.
4. Higgins MJ, Baselga J (2011) Targeted therapies for breast cancer. J Clin Invest 121:3797-3803.
5. Russnes HG, Navin N, Hicks J, Borresen-Dale AL (2011) Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121:3810-3818.
6. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718-2723.
7. Serra V, et al. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547-2557.
8. Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71.
9. Heiser LM, et al. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109:2724-2749.
10. Mendes-Pereira AM, et al. (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109:2730-2735.
11. Jin K, et al. (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 109:2736-2741.
12. Haughian JM, et al. (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 109:2742-2747.
13. Holmes KA, et al. (2012) Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci USA 109:2748-2753.
14. Liberal V, et al. (2012) Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides theDNAdamage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci USA 109:2754-2759.
15. Chiba N, et al. (2012) Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci USA 109:2760-2765.
16. Oakes SR, et al. (2012) Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 109:2766-2771.
17. Keller PJ, et al. (2012) Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 109:2772-2777.
18. Herschkowitz JI, et al. (2012) Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 109:2778-2783.
19. Conley SJ, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109:2784-2789.
20. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273.
21. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S (2010) Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 107:14152-14157.
22. Zhang X, et al. (2012) Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci USA 109:2790-2795.
23. Place AE, Jin Huh S, Polyak K (2011) The microenvironment in breast cancer progression: Biology and implications for treatment. Breast Cancer Res 13:227.
24. Ruffell B, et al. (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 109:2796-2801.
25. Denardo DG, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54-67.
26. Coussens LM, Pollard JW (2011) Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol 3:3.
27. Kristensen VN, et al. (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 109:2802-2807.
28. Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ (2012) Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci USA 109:2808-2813.
29. Owens P, et al. (2012) Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci USA 109:2814-2819.
30. Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: Insights into functions. Nat Rev Genet 10:155-159.
31. Maruyama R, et al. (2012) Altered antisense-to-sense transcript ratios in breast cancer. Proc Natl Acad Sci USA 109:2820-2824.